Miriam C Souroujon Selected Research

Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis)

11/2014	Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.
12/2012	Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis.
3/2011	Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.
2/2011	The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells.
3/2010	Involvement of phosphodiesterases in autoimmune diseases.
4/2009	Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3.
11/2008	Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
9/2008	Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent.
2/2008	A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis.
1/2008	The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: experimental autoimmune myasthenia gravis as a model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Miriam C Souroujon Research Topics

Disease

20	Myasthenia Gravis 01/2020 - 07/2003
18	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 11/2014 - 05/2002
10	Autoimmune Diseases (Autoimmune Disease) 02/2016 - 03/2002
1	Thymus Hyperplasia 02/2016
1	Neuromuscular Diseases (Neuromuscular Disease) 02/2016
1	Muscle Weakness 11/2014
1	Sepsis (Septicemia) 03/2014

Drug/Important Bio-Agent (IBA)

11	Cholinergic ReceptorsIBA 02/2016 - 07/2003
5	AutoantigensIBA 02/2011 - 07/2003
5	Intravenous Immunoglobulins (IVIG)FDA Link 02/2008 - 07/2006
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2005
4	AutoantibodiesIBA 02/2016 - 07/2013
4	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 11/2014 - 07/2005
3	AntibodiesIBA 01/2020 - 07/2005
3	AntigensIBA 01/2020 - 09/2003
2	Interleukin-6 (Interleukin 6)IBA 01/2015 - 03/2011
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 03/2010 - 02/2006
2	CXCR3 ReceptorsIBA 04/2009 - 05/2005
2	EpitopesIBA 09/2003 - 07/2003
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020
1	muskIBA 01/2020
1	EndotoxinsIBA 03/2014
1	ChemokinesIBA 04/2009
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 11/2008
1	Methylprednisolone FDA LinkGeneric 09/2008
1	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2008
1	Pentoxifylline (Trental)FDA LinkGeneric 09/2008
1	SteroidsIBA 09/2008
1	Therapeutic UsesIBA 01/2008
1	Immunoglobulin G (IgG)IBA 09/2007
1	DNA (Deoxyribonucleic Acid)IBA 06/2007
1	Pharmaceutical PreparationsIBA 06/2007
1	Phosphodiesterase InhibitorsIBA 02/2006
1	VaccinesIBA 07/2005
1	CytokinesIBA 09/2003
1	Monoclonal AntibodiesIBA 01/2003
1	Peptides (Polypeptides)IBA 05/2002
1	Interleukin-18 (Interleukin 18)IBA 03/2002

Therapy/Procedure

2	Therapeutics 02/2016 - 09/2008
2	Immunotherapy 12/2012 - 06/2007
1	Intranasal Administration 01/2020
1	Oral Administration 07/2004
1	Mucosal Administration 09/2003